about
What happens to cardiovascular system behind the undetectable level of HIV viremia?Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection.Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals.Neutralizing antibodies against autologous human immunodeficiency virus Type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment.Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced diseaseAssociation between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.Taming HIV-related inflammation with physical activity: a matter of timingReconstitution of intestinal CD4 and Th17 T cells in antiretroviral therapy suppressed HIV-infected subjects: implication for residual immune activation from the results of a clinical trial.Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection.Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing.MicroRNA-29 family expression and its relation to antiviral immune response and viro-immunological markers in HIV-1-infected patientsHigh prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.Teaching tired T cells to fight HIV: time to test IL-15 for immunotherapy?Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial.The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care UnitHigher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.An epidemiological investigation to reconstruct a probable human immunodeficiency virus-1 transmission network: a case report.Microbial translocation and infectious diseases: what is the link?Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfectionEvolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.Effects of raltegravir on 2-long terminal repeat circle junctions in HIV type 1 viremic and aviremic patientsMaraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial.Accelerated coronary atherosclerosis after execution of percutaneous coronary intervention in patient with HIV/HCV coinfection: case report and review of the literature.HIV-associated immune activation: from bench to bedside.Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature.Mutational resistance pattern of HIV type 1 in CD14+ monocytes, CD4+ T cells, and plasma from treated patients.Abdominal aortic mycotic aneurysm, psoas abscess, and aorto-bisiliac graft infection due to Salmonella typhimurium.Urinary schistosomiasis in asylum seekers in Italy: an emergency currently undervalued.A seven-year prospective study on spondylodiscitis: epidemiological and microbiological features.Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.Interleukin-15 enhances the secretion of IFN-gamma and CC chemokines by natural killer cells from HIV viremic and aviremic patients.Central role of interleukin-15 in human immunodeficiency virus (HIV)-infected patients with visceral leishmaniasis.Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy.Discordant response to antiretroviral therapy: HIV isolation, genotypic mutations, T-cell proliferation and cytokine production.Interleukin-15 in HIV infection: immunological and virological interactions in antiretroviral-naive and -treated patients.Interleukin-15 modulates interferon-gamma and beta-chemokine production in patients with HIV infection: implications for immune-based therapy.Presepsin as a potential marker for bacterial infection relapse in critical care patients. A preliminary study.Ex vivo and in vitro effect of human immunodeficiency virus protease inhibitors on neutrophil apoptosis.
P50
Q26749024-BA06CD62-5353-476D-8833-ED26F4E80E23Q30403278-FEDB2E3B-9291-4DE9-A016-4502D61E9DAFQ33269303-2D90BCCF-7328-4E70-BF1C-6F485C738366Q33999316-75F07FCE-7B3D-491A-B35E-052D56D8FB02Q34100037-D494DF53-DA05-4E94-B7BD-5FA20F7318FAQ34231589-EEA47060-D8D7-458B-9019-55D4528DD3DEQ34266259-5B64B5DC-980F-4BCE-9053-EF8DAD61DFD8Q34394987-0CC9E7D3-0E70-4546-A2B5-3D688848A3F6Q34756669-FA91BA18-E8E5-418C-9CA9-F89BF39EEB99Q34869426-81CEC1C3-7AF1-440C-989C-3D5E07022202Q34973832-869B2826-AF26-4998-B4A0-F7E35FB1553EQ35108559-24D56376-BFEA-4A11-8282-6426EFF0F8D0Q35156558-3F1361BE-4D1C-4930-B748-83326B26FC6FQ35702772-F87835C6-840C-4E65-BEBD-1393BD74FC54Q35777447-6EA44AA4-2512-47BC-A497-D7E44B996F16Q35794409-60EED339-F29B-429B-B01D-3F99AF115580Q35935297-743D2CFE-0DFD-4B5C-BE31-039CE2FE30BAQ36102240-E9F04302-CA9E-4A87-B346-6EBD8B5F003EQ36242909-75247B33-6653-429E-86EC-B5AAA21B4917Q36317823-8509496F-814D-412F-92E4-4649EA35CD80Q36467243-0F164EE7-2447-4B34-831C-C6CE30CD4F62Q36632238-53949436-E54E-4AA2-99E1-9DDF7E70BEB7Q37204137-9C8F75DD-0830-400F-AB1C-B393E51295CAQ37308894-9A9747FD-1D20-4879-9A65-1F9817030C88Q37832868-C40B0B7C-5CC6-4961-B3FB-3BC6BE74498AQ37839117-41659EF6-CDC6-4648-8EA6-789F43A52AC6Q37844164-0408B2A0-D169-4583-AD96-FD127319FFA3Q38416368-50ED58C9-ED70-44A7-8A87-61C5681B5CA4Q38932507-1A23FF12-5974-4691-AFAF-E6C2DE05A168Q38935392-117FD527-D219-45C0-8A52-32B5698763D6Q38958999-509E5895-63D9-4340-9B6E-3C5111CF744EQ38959269-4CAA84FF-953A-4A89-B74F-8522FB2BE9A2Q38959273-47125776-4D17-4AFA-A783-390D114DA1BBQ38959278-ABBF5015-3DAF-4CBB-B873-25741632B1F5Q38959284-D8A6B9FA-05EB-41F8-96E6-C0880762B2B5Q38959289-3BD493F2-DC23-42A5-B024-0850DEBC01D4Q38959293-5D80C7C0-2316-4746-8F9D-26F646FD6E2AQ39008104-BBF2FC3A-A5C2-4429-B278-0EEE8A167F5DQ39205985-612BC947-ECEC-4BB3-BCE1-726801D5C7F6Q39223332-F227ACC3-9395-4892-A031-DBE239A5A8B1
P50
description
Italiaans onderzoekster
@nl
Italian researcher
@en
taighdeoir Iodálach
@ga
name
Gabriella d'Ettorre
@an
Gabriella d'Ettorre
@ast
Gabriella d'Ettorre
@ca
Gabriella d'Ettorre
@da
Gabriella d'Ettorre
@de
Gabriella d'Ettorre
@en
Gabriella d'Ettorre
@es
Gabriella d'Ettorre
@eu
Gabriella d'Ettorre
@fr
Gabriella d'Ettorre
@ga
type
label
Gabriella d'Ettorre
@an
Gabriella d'Ettorre
@ast
Gabriella d'Ettorre
@ca
Gabriella d'Ettorre
@da
Gabriella d'Ettorre
@de
Gabriella d'Ettorre
@en
Gabriella d'Ettorre
@es
Gabriella d'Ettorre
@eu
Gabriella d'Ettorre
@fr
Gabriella d'Ettorre
@ga
prefLabel
Gabriella d'Ettorre
@an
Gabriella d'Ettorre
@ast
Gabriella d'Ettorre
@ca
Gabriella d'Ettorre
@da
Gabriella d'Ettorre
@de
Gabriella d'Ettorre
@en
Gabriella d'Ettorre
@es
Gabriella d'Ettorre
@eu
Gabriella d'Ettorre
@fr
Gabriella d'Ettorre
@ga
P106
P1153
6701506536
P21
P27
P31
P496
0000-0002-3571-5677